Through its Soin et Nature division, Almirall offers innovative therapeutic solutions, particularly in the field of gastroenterology, with products such as Spagulax—formulated with ispaghul mucilage—to effectively treat constipation and bowel movement disorders. Thanks to its recognized pharmaceutical expertise, Almirall offers safe and tailored treatments to improve daily digestive comfort.
More details
Founded in 1943 in Barcelona, Almirall isa global pharmaceutical companyspecializing in the treatment of dermatological conditions, chronic inflammatory diseases, gastrointestinal disorders, and neurological pain. With a presence in more than 10 countries, the group develops, manufactures, and markets innovative therapeutic solutions, drawing on more than 80 years of expertise in pharmaceutical research and development.
Today, Almirall is recognized for its major advances in the treatment of skin diseases—including psoriasis, actinic keratosis, andeczema—as well as for its medications targeting migraines, constipation, and certain respiratory and neurological conditions. Its positioning is based on scientific excellence, continuous innovation, and a deep commitment to addressing unmet therapeutic needs.
Almirall actively collaborates with numerous public and private research centers around the world. Among its partners are:
Almirall also participates in several European programs, such asthe Innovative Medicines Initiative. These strategic collaborations fuel the laboratory’s R&Dactivities, enabling the development of safe, effective, and clinically validated medications through rigorous trials and complete transparency regarding published results.
Key milestones in Almirall’s development include:
In 2014, Almirall transferred its respiratory franchise to AstraZeneca in order to focus fully on its core area of expertise: dermatology.
Here are Almirall’s areas of expertise
Dermatology is one of Almirall’s key areas of focus, with a range of innovative medications designed to treat chronic and inflammatory skin conditions:
Almogran: a medication containingalmotriptan, indicated for the acute treatment ofmigraine with or without aura. This latest-generation triptan works by inhibiting the dilation of intracranial blood vessels and reducing the transmission of pain signals.
Vaniqa: a cream containingeflornithine, indicated to slow hair regrowth onwomen’s faces. It works by blocking the enzyme responsible for hair growth.
Beyond dermatology, Almirall develops products in the following areas:
All drugs developed by Almirall are subject to strict quality standards, including Good Manufacturing Practices (GMP), rigorous monitoring of clinical trials, and the transparent publication ofscientific data for prescribers and patients.
The company is committed to bringing to market only products that have demonstrated proven therapeutic efficacy, validated by national and international health authorities.
With over 80 years of history, a presence on several continents, and a specialization in dermatology and specialized medicine, Almirallpositions itselfas a pharmaceutical company focused on the future of therapeutics. Its products aim to effectively address specific medical needs while ensuring safety, accessibility, and constant innovation.
Whether in the treatment of skin conditions, neurological pain, digestive disorders, or chronic conditions, Almirall’s medications provideconcrete clinical solutions, supported by a solid scientific foundation and a policy of responsible development.
